Last reviewed · How we verify
ALX-0081
ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation.
ALX-0081 is a nanobody that specifically targets von Willebrand factor (vWF), reducing its activity and preventing platelet aggregation. Used for Acquired thrombotic thrombocytopenic purpura (aTTP).
At a glance
| Generic name | ALX-0081 |
|---|---|
| Sponsor | Ablynx, a Sanofi company |
| Drug class | Nanobody |
| Target | von Willebrand factor (vWF) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
By binding to the A1 domain of vWF, ALX-0081 inhibits the interaction between vWF and platelets, which is crucial for thrombus formation under high shear stress conditions.
Approved indications
- Acquired thrombotic thrombocytopenic purpura (aTTP)
Common side effects
- Headache
- Nausea
Key clinical trials
- A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (PHASE2, PHASE3)
- Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (PHASE3)
- Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (PHASE2)
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients (PHASE2)
- Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALX-0081 CI brief — competitive landscape report
- ALX-0081 updates RSS · CI watch RSS
- Ablynx, a Sanofi company portfolio CI